Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 5/20 | 0.62 |
| ▸ | CTSL | P07711 | 3/20 | 0.56 |
| ▸ | CTSS | P25774 | 3/20 | 0.56 |
| ▸ | CTSK | P43235 | 3/20 | 0.56 |
| ▸ | CTSH | P09668 | 1/20 | 0.55 |
| ▸ | MC4R | P32245 | 1/20 | 0.54 |
| ▸ | MC5R | P33032 | 1/20 | 0.54 |
| ▸ | MC3R | P41968 | 1/20 | 0.54 |
| ▸ | MC1R | Q01726 | 1/20 | 0.54 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.53 |
| ▸ | CXCL8 | P10145 | 5/20 | 0.52 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.52 |
| ▸ | GLP1R | P43220 | 3/20 | 0.52 |
| ▸ | GCGR | P47871 | 3/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30804655 | 0.87 | CXCR4 (0.66) | CXCR4CTSLCTSSCTSKCTSH | |
| SCHEMBL30992038 | 0.85 | CTSL (0.59) | CXCR4CTSLCTSSCTSKCTSH | |
| SCHEMBL29394617 | 0.85 | CXCR4 (0.71) | CXCR4MC4RMC5RMC3RMC1R | |
| SCHEMBL29614906 | 0.84 | C5AR1 (0.58) | CXCR4MC4RMC5RMC3RMC1R | |
| SCHEMBL31452904 | 0.84 | CTSL (0.62) | CXCR4CTSLCTSSCTSKCTSH | |
| SCHEMBL30582469 | 0.84 | CTSL (0.57) | CXCR4CTSLCTSSCTSKCTSH | |
| SCHEMBL31433222 | 0.84 | CTSL (0.60) | CXCR4CTSLCTSSCTSKCTSH | |
| SCHEMBL30450633 | 0.83 | DPP3 (0.57) | CXCL8 | |
| SCHEMBL31452901 | 0.83 | CXCR4 (0.67) | CXCR4C5AR1CXCL8IL23R | |
| SCHEMBL29476509 | 0.83 | KISS1R (0.55) | CXCR4CTSLCTSSCTSKCTSH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240002547-A1 | THERAPEUTIC MULTI-TARGETING CONSTRUCTS AND USES THEREOF | AEBI LTD (IL) | 2024-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240002547-A1 | THERAPEUTIC MULTI-TARGETING CONSTRUCTS AND USES THEREOF | CD47, GZMB, CD44 | CXCR4 893/4885CTSL 638/4885CTSS 495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.